Both CRISPR Therapeutics AG (NASDAQ:CRSP) and Zealand Pharma A/S (NASDAQ:ZEAL) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||54||0.00||34.37M||-3.74||0.00|
|Zealand Pharma A/S||30||0.00||26.77M||3.00||7.54|
Table 1 highlights CRISPR Therapeutics AG and Zealand Pharma A/S’s gross revenue, earnings per share (EPS) and valuation.
Table 2 has CRISPR Therapeutics AG and Zealand Pharma A/S’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||63,507,021.43%||-50.9%||-39.8%|
|Zealand Pharma A/S||87,914,614.12%||0%||0%|
CRISPR Therapeutics AG and Zealand Pharma A/S Recommendations and Ratings are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||4||3.00|
|Zealand Pharma A/S||0||0||2||3.00|
CRISPR Therapeutics AG has a consensus price target of $66.5, and a -8.11% downside potential. On the other hand, Zealand Pharma A/S’s potential upside is 11.04% and its consensus price target is $36.5. The results provided earlier shows that Zealand Pharma A/S appears more favorable than CRISPR Therapeutics AG, based on analyst opinion.
Institutional & Insider Ownership
CRISPR Therapeutics AG and Zealand Pharma A/S has shares held by institutional investors as follows: 50% and 9%. Insiders held roughly 2% of CRISPR Therapeutics AG’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
|Zealand Pharma A/S||-1.05%||3.57%||8.69%||53.95%||52.19%||94.92%|
For the past year CRISPR Therapeutics AG’s stock price has smaller growth than Zealand Pharma A/S.
Zealand Pharma A/S beats on 8 of the 11 factors CRISPR Therapeutics AG.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.